DOI:
10.1055/s-00000020
Geburtshilfe und Frauenheilkunde
LinksClose Window
References
Piccart M, Procter M, Fumagalli D. et al.
Interim Overall Survival Analysis of APHINITY. A randomised multi-center, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus Pertuzumab versus chemotherapy plus Trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer. SABCS 2019, San Antonio/Texas/USA, Dezember 2019. Oral presentation GS1-4.
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.